Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.  Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a 14-day full dose regimen, preserves C-peptide and increases the percentage of patients requiring very low doses of insulin (< 0.25 U/kg/day) with good glycemic control (glycosylated hemoglobin, or HbA1C < 7%) compared to placebo.  In addition, these analyses revealed that certain subpopulations may be more likely to respond to teplizumab treatment.  These findings also were presented today by Dr. Nicole Sherry (Massachusetts General Hospital for Children) at the annual American Diabetes Association meeting.

Protege is a two-year, randomized, double-blind, placebo-controlled clinical trial, with 513 patients aged 8–35, recently diagnosed with type 1 diabetes, who were enrolled and treated at 83 clinical centers in North America, Europe, Israel, and India. Participants were allocated 2:1:1:1 to receive daily infusions of teplizumab (full dose for 14 days, 1/3 dose for 14 days, or full dose for 6 days) or placebo at baseline and at 6 months. The primary composite endpoint of the Protege study was the percentage of patients with insulin use < 0.5 U/kg/day and HbA1C < 6.5% at 1 year.  Although teplizumab was shown to have an acceptable safety profile, the primary endpoint was not achieved, as had been previously announced in a joint communication with Eli Lilly and Company in October 2010.  Protege is ongoing and will complete the 2-year follow-up in 2011.

The peer-reviewed article appearing in The Lancet is titled, "Teplizumab for treatment of type 1 diabetes (Protege study):
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "Market Assessment ... Europe" report to their offering. ,     (Logo: ... of the respiratory imaging diagnostics market in ... Europe . The service provides detailed ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Jan. 27, 2011 CareCentrix, Inc ., the ... will present tomorrow at the World Congress, 2nd Annual ... William Kerr, Chief Medical Officer, will discuss CareCentrix,s HomeSTAR™ ... of home based interventions. Hospital readmissions ...
... Inc., a global medical technology company focused on improving blood ... 16 inspiring individuals inducted into the company,s 2010 Donation Hall ... decade, Fenwal has partnered with blood centers to recognize people ... medicine,s most vital natural resource -- blood -- is available ...
Cached Medicine Technology:CareCentrix to Present at Hospital Readmissions Conference 22010 Inductees to the Fenwal Blood Donation Hall of Fame 22010 Inductees to the Fenwal Blood Donation Hall of Fame 3
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... The Rolling Stones Zip Code ... Diego at Petco Park. This iconic group is ready ... 20th, they had a warmup show in Los Angeles at ... Los Angeles, this beloved band not only played their Sticky ... such as "Jumping Jack Flash," "Moonlight Mile" and "All ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific consulting ... issues that may have raised the risk of mesothelioma ... posted an article on the research. Click here ... airborne asbestos levels well above OSHA safety guidelines when ... , “Asbestos compliance sampling data associated with the construction, ...
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the leading ... America, Inc. (MTA) has selected IFN as a fiber ... Enterprise Sales Manager, fiber route diversity and network redundancy ... provides MTA with the diverse fiber transport from their ... and voice carriers located at Henry Street in Indianapolis, ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 ... Branches Florida City exactly five years to the day after ... , A large fire tore through the Branches United Methodist ... in the middle of the night as neighbors, staff and ... arson even though it is suspected that the fire began ...
Breaking Medicine News(10 mins):Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2
... MORGANTOWN, W.Va., June 12 In 2010, cancer will ... chronic illnesses such as heart disease and stroke. Already ... combined. Almost three-quarters of new cases will occur in ... sub-Saharan Africa by 2020, according to World Health Organization ...
... Eligible for $3,000 to Attend Online University , ... Governors University , www.wgu.edu , has ... hospitals, the WGU Nursing Partners Scholarship Fund. Registered nurses ... America (HCA), Kaiser Permanente, Catholic Healthcare West, and Universal ...
... HealthSouth Corporation (NYSE: HLS ) announced today ... dividend of $16.25 per share on its 6.5% Series A ... holders of record on July 1, 2009. , ... largest provider of inpatient rehabilitative healthcare services. Operating in 26 ...
... public, even families are involved, study finds , FRIDAY, ... family history of an incurable genetic disease isn,t worry ... report being discriminated against by insurance companies, relatives and ... Yvonne Bombard and colleagues at the University of British ...
... Mobility LLC, a leading provider of mobile content, today announced ... " campaign, which will enable wireless participants to receive health ... Foundation . , , The " Text For a ... issuance of $100 Gift Certificates awarded to select participants on ...
... Copenhagen, Denmark, Friday 12 June 2009: Three new studies ... etanercept to be effective, with a good safety profile, ... idiopathic arthritis (JIA), and associated with improved Health-Related Quality ... with JIA. The data are being presented at the ...
Cached Medicine News:Health News:WVU Doctor Works to Reduce Cancer Burden in Africa 2Health News:Western Governors University Offers Special Nursing Scholarships for Employees of Hospital Partners 2Health News:Western Governors University Offers Special Nursing Scholarships for Employees of Hospital Partners 3Health News:People With Huntington's Report Discrimination 2Health News:People With Huntington's Report Discrimination 3Health News:Salient Mobility Launches the 'Text For a Cause(TM)' Campaign in Raising Awareness Through Wireless Health Tips 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 2Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 3Health News:3 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 4
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Products are constructed of a ... MEROCEL polyvinyl acetal sponge. Each ... beneficial to both surgeon and ... yet firm enough to gently ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
Medicine Products: